Efstratios Tsakalidis

Efstratios Tsakalidis

Auto-generated profile, based on publicly available information

Efstratios Tsakalidis

Division of Pharmaceutical Chemistry Department of Pharmacy National and Kapodistrian University of Athens Athens Greece

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
IAIfigeneia Akrani
Ifigeneia Akrani
DDDanai Driva
Danai Driva
ETEfstratios Tsakalidis
Efstratios Tsakalidis
NMNandini Mozumdar
Nandini Mozumdar
DMDanai Mavridi
Danai Mavridi
VMVassilios Myrianthopoulos
Vassilios Myrianthopoulos
The Set and Ring domain of the UHRF1 oncogene is responsible for its interaction with hemimethylated DNA and faithful propagation of epigenetic signaling over cellular replication. Inhibiting this recognition can have serious implications for UHRF1 functionality and may possibly enable therapeutic interventions. Based on a previous finding indicating a promising in vitro DNA demethylating potential of a pyrimidine derivative, a subscaffold search was performed in the NCI/DTP compound repository to discover similar molecules and evaluate their affinity for the SRA domain of UHRF1. Toward this direction, several compounds were evaluated using a thermal melt screen, and the most promising hits were subsequently studied by calorimetry in terms of their capacity to bind the 5-methylcytosine recognition site of UHRF1. A markedly different thermodynamic profile between the two confirmed hits with an intense enthalpy-entropy compensation signature was determined. The systems were further studied by biased and unbiased molecular simulations, computational hydration mapping, and calorimetry-based heat capacity measurements to devise a hypothesis on the structural requisites for efficient SRA binding. The most potent compound was evaluated for its DNA methylation effects against the UHRF1-dependent colorectal cancer HCT116 cells, where promising global demethylating activity reaching an approximate 75% reduction compared to control was achieved after treatment with 25 μM of NSC232005. Based on the presented results, rationally substituted analogues of the uracil scaffold appear as highly promising UHRF1 modulators for exploring its diverse functionalities and validating the protein as a drug target.

28 August 2026 in ChemMedChem
Verified
Journal Article
Open access
PDF file
ETEfstratios Tsakalidis
Efstratios Tsakalidis
MGMariangela Giannouli
Mariangela Giannouli
IAIfigeneia Akrani
Ifigeneia Akrani
APAnthi Panara
Anthi Panara
EKEleni Katalagarianou
Eleni Katalagarianou
VMVassilios Myrianthopoulos
Vassilios Myrianthopoulos
The tandem Tudor domain (TTD) of UHRF1 is a compelling epigenetic target for novel cancer therapeutics. Here, we integrate theoretical simulations, sophisticated biophysical evaluations and cellular assays to characterize potent TTD binders. Screening of small drug‐ and fragment‐like collections identifies several TTD ligands, with the most promising hit being the local anesthetic hydroxyprocaine. The ligand is characterized in terms of its binding requisites by calorimetry, affording a K d of 1.46 μM and a well‐balanced thermodynamic profile. Molecular dynamics simulations combined with heat capacity measurements and osmotic stress titrations confirm that hydroxyprocaine binds stably to the TTD by displacing approximately 26 interfacial water molecules upon complexation. A targeted follow‐up screen focusing on sodium channel blockers yields two additional, although less promising hits, mexiletine and triamterene. In the DU145 prostate cancer cell line, hydroxyprocaine treatment significantly up‐regulates key downstream targets including the tumor‐suppressor p53 and, to a lesser degree, the stress and inflammation regulators p38 and p65, respectively, while exhibiting very low cytotoxicity. Finally, a previously undocumented interdomain interaction between TTD and its N‐terminal adjacent Ubiquitin‐like domain is reported, introducing a novel, potentially druggable UHRF1 regulatory feature. Together, these findings establish hydroxyprocaine as a highly viable chemical scaffold for TTD‐targeted drug development.